Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Florence BaettigTatjana VlajnicMarcus VetterKatharina GlatzJürgen HenchStephan FrankMichel BihlRoberto LopezMichael DobbieViola Heinzelmann-SchwarzCéline Montavon SartoriusPublished in: Journal for immunotherapy of cancer (2019)
The persistent complete response after third-line treatment for relapsed chemotherapy-resistant cervical cancer presented in this case highlights the potential of immunotherapy for patients with advanced cervical cancer impressively. To our knowledge, this is the first report of an isolated immune-related vulvitis under nivolumab. This adverse event might be underdiagnosed and mistreated, however, it is of importance due to its impact on quality of life, sexual wellbeing and compliance of patients. Successful IRAE management may enable prolonged immune checkpoint inhibitor therapy. In the future, routine molecular tumour profiling is likely to aid in the stratification of cervical cancer patients for immunotherapy. Here, we provide the methylome data of a case with complete response.
Keyphrases
- end stage renal disease
- newly diagnosed
- healthcare
- ejection fraction
- chronic kidney disease
- locally advanced
- acute lymphoblastic leukemia
- acute myeloid leukemia
- prognostic factors
- diffuse large b cell lymphoma
- stem cells
- mental health
- squamous cell carcinoma
- electronic health record
- clinical practice
- bone marrow
- risk assessment
- single cell
- adverse drug
- climate change
- replacement therapy
- current status
- multiple myeloma
- combination therapy